1. Secretome and immune cell attraction analysis of head and neck cancers.
- Author
-
Muijlwijk T, Wondergem NE, Ekhlas F, Remkes N, Nijenhuis DNLM, Fritz L, Ganzevles SH, Miedema IHC, Leemans CR, Poell JB, Brakenhoff RH, and van de Ven R
- Subjects
- Humans, Secretome metabolism, Squamous Cell Carcinoma of Head and Neck immunology, Squamous Cell Carcinoma of Head and Neck metabolism, Squamous Cell Carcinoma of Head and Neck pathology, Cancer-Associated Fibroblasts metabolism, Cancer-Associated Fibroblasts immunology, Chemokines metabolism, Head and Neck Neoplasms immunology, Head and Neck Neoplasms metabolism, Head and Neck Neoplasms pathology, Tumor Microenvironment immunology, Cell Movement, Dendritic Cells immunology, Dendritic Cells metabolism
- Abstract
Immune checkpoint inhibitors are approved for recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) but the response rate is only 13-18%. For an effective antitumor immune response, trafficking of immune cells to the tumor microenvironment (TME) is essential. We aimed to better understand immune cell migration as well as the involved chemokines in HNSCC. A transwell assay was used to study immune cell migration toward TME-conditioned medium. While T cell migration was not observed, conventional dendritic cell (cDC) migration was induced by TME-conditioned media. cDC migration correlated with various proteins in the TME secretome. CCL8, CXCL5, CCL13 and CCL7 were tested in validation experiments and addition of these chemokines induced cDC migration. Using single cell RNA-sequencing, we observed expression of CCL8, CXCL5, CCL13 and CCL7 in cancer-associated fibroblasts (CAFs). Depleting fibroblasts led to reduced cDC migration. Thus CAFs, while often seen as suppressors of antitumor immunity, play a role in attracting cDCs toward the head and neck cancer TME, which might be crucial for effective antitumor immunity and response to therapies. Indeed, we found RNA expression signatures of the indicated chemokines, cDC and CAF subpopulations, to be significantly higher in baseline tumor specimen of patients with a major pathological response to pre-surgical anti-PD-1 treatment compared to non-responding patients., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF